Natixis Advisors, L.P. Incyte Corp Transaction History

Natixis Advisors, L.P.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 25, 2024	BUY	$56.55 - $66.59 $226,030 - $266,160	3,997 Added 32.15%	16,431 $936,000
Q4 2023 Feb 06, 2024	BUY	$52.16 - $64.19 $648,557 - $798,138	12,434 New	12,434 $780,000
Q1 2023 May 11, 2023	BUY	$70.23 - $86.01 $262,730 - $321,763	3,741 Added 9.52%	43,030 $3.11 Million
Q4 2022 Jan 27, 2023	BUY	$67.18 - $84.11 $782,915 - $980,217	11,654 Added 42.17%	39,289 $3.16 Million
Q3 2022 Nov 14, 2022	SELL	$66.18 - $82.86 $266,639 - $333,842	-4,029 Reduced 12.72%	27,635 $1.84 Million
Q2 2022 Aug 12, 2022	BUY	$66.18 - $83.18 $333,150 - $418,728	5,034 Added 18.9%	31,664 $2.41 Million
Q1 2022 May 12, 2022	BUY	$66.02 - $79.71 $1.76 Million - $2.12 Million	26,630 New	26,630 $2.12 Million
Q4 2019 Feb 10, 2020	SELL	$73.04 - $95.72 $791,826 - $1.04 Million	-10,841 Closed	0 $0
Q3 2019 Nov 12, 2019	BUY	$72.82 - $86.52 $789,441 - $937,963	10,841 New	10,841 $805,000

643

186M

714K

557K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $16B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of Natixis Advisors, L.P., based on Form 13F filings with the SEC.

Stay updated on Natixis Advisors, L.P. with notifications on news.